NCT06134635View on ClinicalTrials.gov

Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Not yet recruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

December 1, 2024

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Statins

Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral

DRUG

Evolocumab

Evolocumab 140mg twice a month, subcutaneous injection

All Listed Sponsors
lead

Xuanwu Hospital, Beijing

OTHER

NCT06134635 - Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter